Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.
- Type of security: Non-qualified stock option (right to buy common shares).
- Quantity: 5,000 options.
- Exercise price: $137.46 per share.
- Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
- Expiration: 30 June 2035 (10-year term).
- Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.
The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.